To this date, a single study has analyzed the prognostic role of sPD-1 in NSCLC [12]: In a cohort of 38 EGFR-mutated NSCLC patients, an increase in sPD-1 plasma level during erlotinib therapy was associated with a better prognosis. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.